Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idursulfase-beta (GC1111) Phase 2 in Hunter Syndrome
NCT02663024Phase 2Unknown
- Sponsor
- GC Biopharma
- Start
- Dec 2016
- Primary completion
- Dec 2019
- Modality
- Replacement Enzymes
01
Overview
Phase 2, randomised, double-blind trial of Idursulfase beta in mucopolysaccharidosis type II (4 arms), sponsored by GC Biopharma. Primary endpoint: Percent change from baseline in urinary Glycosaminoglycans at 25 weeks. Status: unknown.
02
Drugs
Idursulfase beta
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT02663024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02663024.